Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Morbid obesity among people with diabetes is increasing at a very alarming rate, says kidney expert

A Loyola University Health System study has found that one out of five Type 2 diabetics is morbidly obese -- approximately 100 pounds or more overweight.

23 Nov 2009

FDA grants Fast Track designation for ARCA biopharma's Gencaro

ARCA biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of GencaroTM, the Company’s investigational, pharmacologically unique beta-blocker and mild vasodilator, for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population.

23 Nov 2009

Isis Pharmaceuticals CEO's letter to shareholders

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

23 Nov 2009

Medical report showing the devastating impacts of coal on human body released

Physicians for Social Responsibility today released a groundbreaking medical report, "Coal's Assault on Human Health," which takes a new look at the devastating impacts of coal on the human body.

23 Nov 2009

Inaugural recipient of the Pfizer/Heart and Stroke Foundation Chair chosen

Renowned B.C. kinesiologist and heart disease researcher Dr. Scott Lear is the inaugural recipient of the Pfizer/Heart and Stroke Foundation Chair in Cardiovascular Disease Prevention Research at St. Paul's Hospital, established in partnership with Simon Fraser University (SFU).

21 Nov 2009

Review of study presented at American Heart Association Scientific Sessions

Adding the cholesterol drug niacin to a statin improved HDL ("good") cholesterol levels and significantly reduced carotid arterial plaque buildup measured with ultrasound within 8 months, with further improvement seen at the end of the study (14 months).

21 Nov 2009

Emotionally abused children may face accelerated cellular aging as adults

Children who suffer physical or emotional abuse may be faced with accelerated cellular aging as adults, according to new research from Butler Hospital and Brown University.

21 Nov 2009

Whole genome analysis identifies 43 genetic loci contributing to lipoprotein metabolism

Using highly precise measurements of plasma lipoprotein concentrations determined by nuclear magnetic resonance spectroscopy (NMR), researchers led by Daniel Chasman at Brigham and Women's Hospital and Harvard Medical School in Boston, MA, the Framingham Heart Study in Framingham, and the PROCARDIS consortium in Stockholm, Sweden and Oxford, England performed genetic association analysis across the whole genome among 17,296 women of European ancestry from the Women's Genome Health Study.

21 Nov 2009

Employers take action to improve medication adherence

More employers are taking steps to improve their employees' health by making sure they take their medicines as prescribed, a move that could stave off more serious and costly health consequences, according to a new report sponsored by the National Pharmaceutical Council (NPC).

21 Nov 2009

ESC and EASD organize Joint Scientific Forum in China to address optimal treatment strategies for diabetes

As a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD), two of the most respected professional medical organisations in Europe, will be held from 27-29 November at three venues across China - Beijing, Shanghai and Guangzhou.

21 Nov 2009

FDA approves sNDA for pediatric autism drug ABILIFY

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.

20 Nov 2009

POZEN commences enrollment in PA32540 phase 3 study

POZEN Inc. announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.

20 Nov 2009

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

New education strategies for better controlling hypertension and research suggesting a possible link between short-term and long-term exposure to air pollution and increased risk of constricted blood vessels are among the research highlights from studies supported by the National Heart, Lung, and Blood Institute (NHLBI) at the American Heart Association's 2009 Scientific Sessions in Orlando held Nov. 14-18.

20 Nov 2009

High blood pressure: A major risk factor for stroke and heart disease

Today, Jamieson Laboratories, in partnership with the Victorian Order of Nurses (VON), is holding a one day Blood Pressure Blitz in Toronto's underground PATH system in an effort to educate consumers about the number one risk factor for stroke and a major risk factor of heart disease.

20 Nov 2009

Sleep apnea is associated with cardiovascular risk factors among kidney transplant patients

Sleep apnea is common in individuals who receive a kidney transplant and is associated with increased risk of high blood pressure, heart disease or stroke, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

20 Nov 2009

Toddlers and obese children suffer more than youth when exposed to secondhand smoke

Toddlers and obese children suffer more than other youth when exposed to secondhand smoke, according to research presented at the American Heart Association's Scientific Sessions 2009.

19 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

Pfizer Canada accepted the Prix Galien Canada 2009 Innovative Product Award for CHAMPIX (varenicline tartrate), the first prescription treatment for smoking cessation in adults specifically designed to target nicotine addiction. The award was presented last night at a gala in Ottawa recognizing excellence in pharmaceutical research.

18 Nov 2009

Phase 2/3 study results of Genzyme's APB announced

Genzyme Corporation today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela® (sevelamer carbonate).

18 Nov 2009

KAI Pharmaceuticals to receive manufacturing services from Formatech

Today, Formatech announced that they have selected KAI Pharmaceuticals, Inc. and their KAI-4169 compound as the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy Program.

18 Nov 2009

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Morbid obesity among people with diabetes is increasing at a very alarming rate, says kidney expert

FDA grants Fast Track designation for ARCA biopharma's Gencaro

Isis Pharmaceuticals CEO's letter to shareholders

Medical report showing the devastating impacts of coal on human body released

Inaugural recipient of the Pfizer/Heart and Stroke Foundation Chair chosen

Review of study presented at American Heart Association Scientific Sessions

Emotionally abused children may face accelerated cellular aging as adults

Whole genome analysis identifies 43 genetic loci contributing to lipoprotein metabolism

Employers take action to improve medication adherence

ESC and EASD organize Joint Scientific Forum in China to address optimal treatment strategies for diabetes

FDA approves sNDA for pediatric autism drug ABILIFY

POZEN commences enrollment in PA32540 phase 3 study

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

High blood pressure: A major risk factor for stroke and heart disease

Sleep apnea is associated with cardiovascular risk factors among kidney transplant patients

Toddlers and obese children suffer more than youth when exposed to secondhand smoke

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

Phase 2/3 study results of Genzyme's APB announced

KAI Pharmaceuticals to receive manufacturing services from Formatech

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in